Insecticides India Q1 FY27 Revenue at ₹616.48 Crore, Profit ₹418.30 Crore
Insecticides (India) Limited reported Q1 FY27 standalone revenue from operations at ₹616.48 crore and profit after tax at ₹41.83 crore. Consolidated revenue was ₹616.87 crore with profit after tax at ₹43.87 crore. The company announced these results on August 11, 2026.
The announcement of quarterly financial results is a routine event for publicly listed companies and provides key financial information to investors. The positive performance suggests a moderate impact on investor sentiment and stock valuation.
The company reported a significant increase in revenue and profit for the quarter compared to the previous year, indicating positive financial performance.
Insecticides (India) Limited has announced its un-audited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors, in their meeting held on August 11, 2026, approved these results.
For the standalone results, the company reported a total income of ₹62,110.58 lakh (₹621.11 crore) for the quarter ended June 30, 2026. Expenses amounted to ₹56,484.11 lakh (₹564.84 crore), leading to a profit before tax of ₹5,626.47 lakh (₹56.26 crore). The profit for the period after tax was ₹4,183.05 lakh (₹41.83 crore). Basic and diluted Earnings Per Share (EPS) stood at ₹14.38.
The consolidated financial results for the same period showed a total income of ₹61,686.70 lakh (₹616.87 crore) and a profit before tax of ₹5,882.05 lakh (₹58.82 crore). The profit for the period after tax was ₹4,387.44 lakh (₹43.87 crore). Consolidated basic and diluted EPS were ₹15.08.
The financial results were reviewed by the Audit Committee and approved by the Board. The Limited Review Report from the Statutory Auditors, M/s S S Kothari Mehta & Co., LLP and M/s Devesh Parekh & Co., has also been made available. The meeting commenced at 12:00 Noon IST and concluded at 02:30 PM IST.
What to do with a filing like this
Insecticides (India) Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Insecticides (India) Limited. Read the original for the full detail.